Talk:Telomere
Script error: No such module "Banner shell". User:MiszaBot/config
Wiki Education Foundation-supported course assignment
File:Sciences humaines.svg This article was the subject of a Wiki Education Foundation-supported course assignment, between 27 January 2020 and 8 May 2020. Further details are available on the course page. Student editor(s): Malaika1089. Peer reviewers: Random from the burgh.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 10:49, 17 January 2022 (UTC)Script error: No such module "Check for unknown parameters".
Histone Modifications in Telomeres
I removed this section from the main wikipedia page because it is likely only of interest to specialists (maybe just the author shilling their own work?) and the article is already too sprawling and hard to read.
The telomeres of human cells have been found to have a unique histone modification pattern, with the most enriched modifications being H2BK5me1 and H3K3me3 and the least enriched modifications being H3K36me3 and H3K9me3 [1]
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "Citation/CS1".
Script error: No such module "Check for unknown parameters".
Wiki Education assignment: Developmental and Molecular Biology Spring 2022
Template:Dashboard.wikiedu.org assignment
telomere biology disorders
Imho the article is missing a section with regards to telomere biology disorders and related diseases:
https://www.nature.com/articles/s41576-022-00527-z Genetics of human telomere biology disorders https://www.annualreviews.org/content/journals/10.1146/annurev-genom-010422-091101 The Role of Telomeres in Human Disease
https://en.wikipedia.org/wiki/Danazol#Research
A 2016 phase I/II prospective study orally administered 800 mg per day to 27 patients with telomere diseases. The primary efficacy endpoint was a 20% reduction in the annual rate of telomere attrition measured. Toxic effects formed the primary safety endpoint. The study was halted early, after telomere attrition was reduced in all 12 patients who could be evaluated. 12 of 27 patients achieved the primary efficacy end point, 11 of whom increased telomere length at 24 months. Hematologic responses (secondary efficacy endpoint) occurred in 10 of 12 patients who could be evaluated at 24 months. Elevated liver-enzyme levels and muscle cramps (known adverse effects) of grade 2 or less occurred in 41% and 33% of the patients, respectively.[1] Agentjoerg (talk) 13:47, 8 November 2024 (UTC)
- ↑ Script error: No such module "Citation/CS1".